Literature DB >> 35038799

[Clinical application of slope-reducing tibial osteotomy and anterior cruciate ligament revision in patients with abnormally increased posterior tibial slope].

Gang Li1, Xuebin Sun1, Keyuan Zhang1, Yang Liu1.   

Abstract

OBJECTIVE: To investigate the effectiveness of slope-reducing tibial osteotomy and anterior cruciate ligament (ACL) revision in the treatment of patients with primary ACL reconstruction failure and abnormally increased posterior tibial slope (PTS).
METHODS: The clinical data of 9 patients with primary ACL reconstruction failure and abnormally increased PTS (≥17°) who met the selection criteria between January 2018 and January 2020 were retrospectively analyzed. There were 8 males and 1 female; the age ranged from 21 to 42 years, with a median age of 30 years. Lachman test was positive in 9 patients. Pivot-shift test was negative in 6 cases, degree Ⅰ positive in 2 cases, and degree Ⅱ positive in 1 case. The PTS was (17.78±1.09)° and the anterior tibial translation (ATT) was (11.58±1.47) mm. The International Knee Documentation Committee (IKDC) score was 51.0±3.8, Lysholm score was 49.7±4.6, and Tegner score was 3.7±0.7. The time from primary reconstruction to revision was 12-33 months, with an average of 19.6 months. Slope-reducing tibial osteotomy and ACL revision were performed. The improvement of knee function was evaluated by IKDC score, Lysholm score, and Tegner score; Lachman test and Pivot-shift test were used to evaluate the stability of knee joint. PTS and ATT were measured to observe the morphological changes of knee joint.
RESULTS: All the incisions healed by first intention, and there was no complication such as incision infection, fat liquefaction, necrosis, deep vein thrombosis of lower extremities, and neurovascular injury. All 9 patients were followed up 12-36 months, with an average of 25.8 months. At last follow-up, Lachman test and pivot-shift test were negative. IKDC score was 85.0±4.0, Lysholm score was 87.7±2.8, Tegner score was 6.8±0.7, PTS reduced to (9.89±0.60)°, and ATT shortened to (0.91±0.29) mm, which were significantly improved when compared with those before operation ( P<0.05).
CONCLUSION: Slope-reducing tibial osteotomy and ACL revision in the treatment of patients with primary ACL reconstruction failure and abnormally increased PTS has a satisfactory short-term effectiveness. It can improve the stability of knee joint and maintain the normal shape of knee joint.

Entities:  

Keywords:  Posterior tibial slope; anterior cruciate ligament; anterior tibial translation; revision; slope-reducing tibial osteotomy

Mesh:

Year:  2022        PMID: 35038799      PMCID: PMC8844632          DOI: 10.7507/1002-1892.202108088

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  20 in total

1.  Development and validation of a new method for the radiologic measurement of the tibial slope.

Authors:  S Utzschneider; M Goettinger; P Weber; A Horng; C Glaser; V Jansson; P E Müller
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-02-05       Impact factor: 4.342

Review 2.  Revision Anterior Cruciate Ligament Reconstruction.

Authors:  Matthew J Kraeutler; K Linnea Welton; Eric C McCarty; Jonathan T Bravman
Journal:  J Bone Joint Surg Am       Date:  2017-10-04       Impact factor: 5.284

3.  Revision Anterior Cruciate Ligament Reconstruction Outcomes at a Minimum of 5-Year Follow-Up: A Systematic Review.

Authors:  Rick W Wright; Lea Johnson; Robert H Brophy; Ljiljana Bogunovic; Matthew J Matava; Matthew V Smith
Journal:  J Knee Surg       Date:  2018-04-13       Impact factor: 2.757

4.  High variability of tibial slope measurement methods in daily clinical practice: Comparisons between measurements on lateral radiograph, magnetic resonance imaging, and computed tomography.

Authors:  Jan-Hendrik Naendrup; Sabrina F Drouven; Humza S Shaikh; Vera Jaecker; Christoph Offerhaus; Sven T Shafizadeh; Thomas R Pfeiffer
Journal:  Knee       Date:  2020-02-12       Impact factor: 2.199

5.  Inferior results after revision ACL reconstructions: a comparison with primary ACL reconstructions.

Authors:  Tone Gifstad; Jon Olav Drogset; Annja Viset; Torbjørn Grøntvedt; Grete Sofie Hortemo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-12-14       Impact factor: 4.342

6.  Increased Lateral Tibial Slope Is a Risk Factor for Pediatric Anterior Cruciate Ligament Injury: An MRI-Based Case-Control Study of 152 Patients.

Authors:  David M Dare; Peter D Fabricant; Moira M McCarthy; Brian J Rebolledo; Daniel W Green; Frank A Cordasco; Kristofer J Jones
Journal:  Am J Sports Med       Date:  2015-07       Impact factor: 6.202

7.  Re-revision Anterior Cruciate Ligament Reconstruction: An Evaluation From the Norwegian Knee Ligament Registry.

Authors:  Alexander R Vap; Andreas Persson; Anne Marie Fenstad; Gilbert Moatshe; Robert F LaPrade; Lars Engebretsen
Journal:  Arthroscopy       Date:  2019-04-30       Impact factor: 4.772

8.  Posterior tibial slope influences static anterior tibial translation in anterior cruciate ligament reconstruction: a minimum 2-year follow-up study.

Authors:  Yue Li; Lei Hong; Hua Feng; Qianqian Wang; Jin Zhang; Guanyang Song; Xingzuo Chen; Hongwu Zhuo
Journal:  Am J Sports Med       Date:  2014-02-19       Impact factor: 6.202

9.  Steep Posterior Tibial Slope and Excessive Anterior Tibial Translation Are Predictive Risk Factors of Primary Anterior Cruciate Ligament Reconstruction Failure: A Case-Control Study With Prospectively Collected Data.

Authors:  Qian-Kun Ni; Guan-Yang Song; Zhi-Jun Zhang; Tong Zheng; Zheng Feng; Yan-Wei Cao; Hua Feng; Hui Zhang
Journal:  Am J Sports Med       Date:  2020-08-31       Impact factor: 6.202

10.  Re-revision anterior cruciate ligament reconstruction showed more laxity than revision anterior cruciate ligament reconstruction at a minimum 2-year follow-up.

Authors:  Kyoung Ho Yoon; Jae Ho Kim; Yoo Beom Kwon; Eung Ju Kim; Sang-Gyun Kim
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-08-05       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.